IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC ...

252
IARC MONOGRAPHS VOLUME 82
Buetler, T.M., Bammler, T.K., Hayes, J.D. & Eaton, D.L. (1996) Oltipraz-mediated changes in
aflatoxin B 1 biotransformation in rat liver: Implications for human chemointervention.
Cancer Res., 56, 2306–2313
Buetow, K.H., Sheffield, V.C., Zhu, M., Zhou, T., Shen, F.-M., Hino, O., Smith, M., McMahon,
B.J., Lanier, A.P., London, W.T., Redeker, A.G. & Govindarajan, S. (1992) Low frequency of
p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc.
natl Acad. Sci. USA, 89, 9622–9626
Bulatao-Jayme, J., Almero, E.M., Castro, M.C., Jardeleza, M.T. & Salamat, L.A. (1982) A case–
control dietary study of primary liver cancer risk from aflatoxin exposure. Int. J. Epidemiol.,
11, 112–119
Campbell, T.C., Chen, J.S., Liu, C.B., Li, J.Y. & Parpia, B. (1990) Nonassociation of aflatoxin
with primary liver cancer in a cross-sectional ecological survey in the People’s Republic of
China. Cancer Res., 50, 6882–6893
Cariello, N.F., Cui, L. & Skopek, T.R. (1994) In vitro mutational spectrum of aflatoxin B 1 in the
human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res., 54, 4436–4441
Casciano, D.A., Chou, M., Lyn-Cook, L.E. & Aidoo, A. (1996) Calorie restriction modulates
chemically induced in vivo somatic mutation frequency. Environ. mol. Mutag., 27, 162–164
Castegnaro, M. & Pfohl-Leszkowicz, A. (1999) Aflatoxins. In: Les Mycotoxines dans l’Alimentation:
Evaluation et Gestion du Risque [Mycotoxins in Food: Risk Evaluation and Management],
Paris, Technique et Documentation, pp. 199–247
Castegnaro, M., Hunt, D.C., Sansone, E.B., Schuller, P.L., Siriwardana, M.G., Telling, G.M., van
Egmond, H.P. & Walker, E.A., eds (1980) Laboratory Decontamination and Destruction of
Aflatoxins B 1, B 2, G 1, G 2 in Laboratory Wastes (IARC Scientific Publications No. 37), Lyon,
IARCPress
Castegnaro, M., Pleština, R., Dirheimer, G., Chernozemsky, I.N. & Bartsch, H., eds (1991) Mycotoxins,
Endemic Nephropathy and Urinary Tract Tumours (IARC Scientific Publications
No. 115), Lyon, IARCPress
Challen, C., Lunec, J., Warren, W., Collier, J. & Bassendine, M.F. (1992) Analysis of the p53
tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology, 16,
1362–1366
Chao, T.C., Maxwell, S.M. & Wong, S.Y. (1991) An outbreak of aflatoxicosis and boric acid
poisoning in Malaysia: A clinicopathological study. J. Pathol., 164, 225–233
Chemin, I., Takahashi, S., Belloc, C., Lang, M.A., Ando, K., Guidotti, L.G., Chisari, F.V. & Wild,
C.P. (1996) Differential induction of carcinogen metabolizing enzymes in a transgenic mouse
model of fulminant hepatitis. Hepatology, 24, 649–656
Chemin, I., Ohgaki, H., Chisari, F.V. & Wild, C.P. (1999) Altered expression of hepatic carcinogen
metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various
amounts of hepatitis B surface antigen. Liver, 19, 81–87
Chen, J. (1997) Dietary Aflatoxin Intake Levels in China: Data Compilation (information submitted
to WHO)
Chen, C.J., Wang, L.Y., Lu, S.N., Wu, M.H., You, S.L., Zhang, Y.J., Wang, L.W. & Santella, R.M.
(1996) Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology,
24, 38–42
Chen, J.X., Zheng, Y., West, M. & Tang, M.-S. (1998) Carcinogens preferentially bind at
methylated CpG in the p53 mutational hot spots. Cancer Res., 58, 2070–2075